- Home
- FUN vs APLS Comparison
FUN vs APLS Comparison
Compare FUN & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUN
- APLS
- Stock Information
- Founded
- FUN 1983
- APLS 2009
- Country
- FUN United States
- APLS United States
- Employees
- FUN N/A
- APLS N/A
- Industry
- FUN Services-Misc. Amusement & Recreation
- APLS Biotechnology: Pharmaceutical Preparations
- Sector
- FUN Consumer Discretionary
- APLS Health Care
- Exchange
- FUN Nasdaq
- APLS Nasdaq
- Market Cap
- FUN 4.6B
- APLS 4.0B
- IPO Year
- FUN 1987
- APLS 2017
- Fundamental
- Price
- FUN $45.36
- APLS $30.13
- Analyst Decision
- FUN Strong Buy
- APLS Buy
- Analyst Count
- FUN 14
- APLS 18
- Target Price
- FUN $56.21
- APLS $46.71
- AVG Volume (30 Days)
- FUN 1.1M
- APLS 2.1M
- Earning Date
- FUN 02-27-2025
- APLS 02-25-2025
- Dividend Yield
- FUN 1.34%
- APLS N/A
- EPS Growth
- FUN N/A
- APLS N/A
- EPS
- FUN 0.37
- APLS N/A
- Revenue
- FUN $2,392,739,000.00
- APLS $715,216,000.00
- Revenue This Year
- FUN $84.97
- APLS $95.82
- Revenue Next Year
- FUN $3.85
- APLS $12.02
- P/E Ratio
- FUN $123.52
- APLS N/A
- Revenue Growth
- FUN 33.41
- APLS 162.10
- 52 Week Low
- FUN $35.93
- APLS $24.34
- 52 Week High
- FUN $58.70
- APLS $71.90
- Technical
- Relative Strength Index (RSI)
- FUN 43.66
- APLS 44.83
- Support Level
- FUN $44.50
- APLS $27.61
- Resistance Level
- FUN $45.89
- APLS $30.13
- Average True Range (ATR)
- FUN 1.63
- APLS 1.50
- MACD
- FUN -0.45
- APLS -0.35
- Stochastic Oscillator
- FUN 29.33
- APLS 33.82
About FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement-resort operator with 27 amusement parks, 15 water parks and nine resort properties across 17 states in the U.S., Canada and Mexico. Six Flags provides coasters, themed rides, thrilling water parks, resorts and a portfolio of beloved intellectual property such as Looney Tunes, DC Comics and PEANUTS.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.